ArticleHeadache2022

Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.

Michel D Ferrari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.